Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | May 22, 2026 | May 26, 2026 |
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 12, 2024 | June 14, 2024 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director · Chief Executive Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date May 22, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 95,210 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 45,871 · Balance 95,210 F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer.
Bolt Biotherapeutics, Inc.
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2034-06-11 | Direct | 22,000 |
Reported balance
After 2024-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 22,000 · Balance 22,000 F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Pacira BioSciences, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 660,830.841 |
Reported balance
After 2026-02-11 transaction · row 1
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 261,818 · Balance 660,830.841 F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forma Therapeutics Holdings, Inc.
Report date October 14, 2022 · Filed October 14, 2022
Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 1
1 source rowRow 1 · 2022-10-14 · Other · Disposed 201,436 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.05 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-14 · Disposition to issuer · Disposed 678,357 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.05 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-14 · Disposition to issuer · Disposed 70,134 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.43 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-14 · Disposition to issuer · Disposed 748,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-14 · Disposition to issuer · Disposed 71,770 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.61 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-14 · Disposition to issuer · Disposed 175,875 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 | Direct | 0 |
Reported balance
After 2022-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-14 · Disposition to issuer · Disposed 182,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.
F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 26, 2026 22:25 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 45,871 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-26-000078 · form4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,210 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value of $250,000, vest on the date immediately preceding the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| May 19, 2026 Filed May 20, 2026 21:41 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 24,456 | $5.43 | $132,796.08 |
DisclosureSEC source: 0000885590-26-000063 · form4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,339 F1 · shares: Represents shares of the Issuer's common stock, no par value, sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 261,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008074 · wk-form4_1771016507.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,830.841 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 41,488 | $20.54 | $852,163.52 |
DisclosureSEC source: 0001628280-26-005153 · wk-form4_1770161015.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,012.841 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 9,272 | $24.46 | $226,793.12 |
DisclosureSEC source: 0001628280-26-000966 · wk-form4_1767738633.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,500.841 F1 · shares: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. F2 · balance_after: Includes 1,363.841 shares of common stock acquired under the issuer's employee stock purchase plan in June 2025. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 20:19 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 15,912 | $7.66 | $121,885.92 |
DisclosureSEC source: 0001127602-25-020878 · form4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,795 F1 · shares: Represents shares of common stock, no par value, of the Issuer sold in the open market to provide funds for estimated tax payments arising from a previously vested equity award granted to the Issuer's non-employee directors. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.66 to $7.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:36 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 54,347 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015034 · form4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,707 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 23:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000031 · wk-form4_1738711538.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,409 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Tax withholdingCommon Stock | 9,375 | $18.33 | $171,843.75 |
DisclosureSEC source: 0001396814-25-000008 · wk-form4_1736205793.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,409 F1 · kind: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:55 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 8,264 | $12.10 | $99,994.40 |
DisclosureSEC source: 0001396814-24-000112 · wk-form4_1723582498.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,784 Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:54 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073892 · ownership.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:08 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 35,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016114 · form4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,360 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of the Issuer on the third business day following their election at the Issuer's Annual Meeting of Shareholders. The RSUs have a grant date value equal to $250,000, vest immediately prior to the Issuer's next Annual Meeting of Shareholders, and are settled in common shares, no par value, of the Issuer. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 22:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 692,512 | $0.00 Strike: $32.07 | $0.00 |
DisclosureSEC source: 0001396814-24-000012 · wk-form4_1704406869.xml · derivative · entry 2 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 692,512 Underlying: Common Stock · 692,512 shares Expires 2034-01-03 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 99,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000012 · wk-form4_1704406869.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,520 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:16 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-037109 · doc4.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 182,500 | Not disclosed Strike: $9.86 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 7 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 175,875 | Not disclosed Strike: $38.61 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 6 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,875 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 71,770 | Not disclosed Strike: $20.00 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 5 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,770 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 748,100 | Not disclosed Strike: $5.43 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 4 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 748,100 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,134 | Not disclosed Strike: $5.05 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 3 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,134 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | Disposition to issuerStock Option (Right to Buy) · Derivative | 678,357 | Not disclosed Strike: $5.05 | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · derivative · entry 2 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 678,357 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 16:07 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | OtherCommon Stock | 201,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033656 · doc4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-22-036081 · doc4.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:21 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 14,071 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012463 · doc4.xml · derivative · entry 2 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,071 Underlying: Common Stock · 14,071 shares Expires 2032-03-23 F2 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:21 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,140 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012463 · doc4.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,140 Underlying: Common Stock · 22,140 shares Expires 2032-03-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of November 17, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:17 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 182,500 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000899243-22-008647 · doc4.xml · derivative · entry 2 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,500 Underlying: Common Stock · 182,500 shares Expires 2032-02-27 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:17 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 121,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008647 · doc4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,436 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 17:08 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | SaleCommon Stock | 17,981 | $9.78 | $175,809.23 |
DisclosureSEC source: 0000899243-22-007923 · doc4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,769 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.61 to $10.005. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 22:35 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 27,860 | $0.00 Strike: $9.01 | $0.00 |
DisclosureSEC source: 0001209191-21-065892 · doc4.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,860 Underlying: Common Stock · 27,860 shares Expires 2031-11-16 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of November 17, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:23 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 175,875 | $0.00 Strike: $38.61 | $0.00 |
DisclosureSEC source: 0000899243-21-009149 · doc4.xml · derivative · entry 3 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,875 Underlying: Common Stock · 175,875 shares Expires 2031-02-25 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2022, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:23 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009149 · doc4.xml · nonDerivative · entry 2 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,750 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:23 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 57,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009149 · doc4.xml · nonDerivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:36 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 71,770 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017441 · doc4.xml · derivative · entry 1 Lee Frank D. · CIK 0001814686 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,770 shares Expires 2030-06-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on June 18, 2021 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.